Published in Clin Interv Aging on August 09, 2010
Radiation Therapy in Treating Patients With Stage II Prostate Cancer | NCT00033631
Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract (2010) 1.13
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab (2011) 0.96
Are clinically insignificant prostate cancers really insignificant among Korean men? Yonsei Med J (2012) 0.88
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer (2013) 0.84
Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study. Soc Sci Med (2016) 0.76
The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study. BMC Urol (2015) 0.75
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol (2006) 5.20
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol (2010) 4.60
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol (2008) 4.11
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys (2001) 3.70
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol (2008) 2.85
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol (2006) 2.50
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol (2009) 1.97
Comparison of radical prostatectomy techniques: open, laparoscopic and robotic assisted. Int Braz J Urol (2008) 1.84
Clinical practice. Localized prostate cancer. N Engl J Med (2007) 1.72
Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol (2000) 1.71
A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer (2006) 1.65
Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.60
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol (2003) 1.60
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (2005) 1.57
Single-port laparoscopic radical prostatectomy. Urology (2008) 1.49
Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology (2009) 1.45
The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol (2008) 1.43
Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol (2008) 1.40
Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol (2006) 1.35
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology (2007) 1.20
Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it? Semin Radiat Oncol (2008) 1.16
Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol (2008) 1.14
History of cryosurgery. Semin Surg Oncol (1998) 1.11
Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol (2006) 1.06
Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol (2009) 1.04
The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol (2000) 1.02
(Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys (2003) 1.01
Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology (2010) 1.00
Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology (2008) 0.99
Do high-volume hospitals and surgeons provide better care in urologic oncology? Urol Oncol (2009) 0.99
Robotic-assisted radical prostatectomy: a review of current outcomes. BJU Int (2009) 0.97
High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy (2009) 0.97
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol (2006) 0.94
Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol (2008) 0.94
Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int (2009) 0.92
Prostate cancer in the elderly. Urol Oncol (2009) 0.92
Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology (2007) 0.91
A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer (2009) 0.90
Transition from pure laparoscopic to robotic-assisted radical prostatectomy: a single surgeon institutional evolution. Urol Oncol (2010) 0.88
Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. J Endourol (2007) 0.87
Cryoablation of the prostate: technical recommendations. Prostate Cancer Prostatic Dis (2009) 0.87
Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both? Strahlenther Onkol (2007) 0.83
Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone. Brachytherapy (2009) 0.81
Clinical decisions. Management of prostate cancer--polling results. N Engl J Med (2009) 0.79
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol (2009) 3.29
Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology (2005) 2.15
Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol (2011) 1.86
Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer (2011) 1.76
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol (2003) 1.57
Contrast enhanced ultrasound flash replenishment method for directed prostate biopsies. J Urol (2007) 1.55
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol (2013) 1.53
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res (2006) 1.46
Multi-institutional survey of laparoscopic ureterolysis for retroperitoneal fibrosis. Urology (2007) 1.46
Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology (2009) 1.45
Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT. Urology (2009) 1.43
Percutaneous cryoablation for recurrent low grade renal cell carcinoma after failed nephron-sparing surgery. Can J Urol (2013) 1.38
Laparoscopy and urologic oncology--I now pronounce you man and wife. J Urol (2003) 1.38
Pseudomass of the bladder neck after prostatectomy: report of two cases. Radiology (2003) 1.38
Current prostate cancer treatments: effect on quality of life. Urology (2009) 1.25
Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem (2011) 1.21
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res (2009) 1.17
Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol (2012) 1.16
Quality improvement in laparoscopic radical prostatectomy for pT2 prostate cancer: impact of video documentation review on positive surgical margin. J Urol (2005) 1.14
The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol (2010) 1.13
Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract (2010) 1.13
Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer (2005) 1.11
Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol (2009) 1.08
Face, content, and construct validation of the da Vinci Skills Simulator. Urology (2012) 1.07
Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases. BMC Urol (2004) 1.05
Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology (2007) 1.04
Contrast-enhanced US of the prostate with Sonazoid: comparison with whole-mount prostatectomy specimens in 12 patients. Radiology (2002) 1.04
FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol (2002) 1.03
Attitudes and use of complementary medicine in men with prostate cancer. J Urol (2002) 1.02
Comparison of lymph node yield in robot-assisted laparoscopic prostatectomy with that in open radical retropubic prostatectomy. BJU Int (2010) 0.98
The quality-of-life impact of prostate cancer treatments. Curr Urol Rep (2010) 0.98
Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis (2009) 0.97
Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res (2013) 0.96
Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys (2011) 0.96
Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer. Urology (2010) 0.96
Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem (2004) 0.95
Prostate: high-frequency Doppler US imaging for cancer detection. Radiology (2002) 0.95
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials (2007) 0.94
Directed biopsy during contrast-enhanced sonography of the prostate. AJR Am J Roentgenol (2002) 0.93
Androgen suppression strategies for prostate cancer: is there an ideal approach? Curr Urol Rep (2011) 0.93
Rhabdomyolysis after laparoscopic nephrectomy. JSLS (2008) 0.92
Hand assisted laparoscopic partial nephrectomy for peripheral and central lesions: a review of 30 consecutive cases. J Urol (2004) 0.92
Quantitative computed tomography perfusion of prostate cancer: correlation with whole-mount pathology. Clin Prostate Cancer (2005) 0.91
Preemptive multimodal pain regimen reduces opioid analgesia for patients undergoing robotic-assisted laparoscopic radical prostatectomy. Urology (2010) 0.91
Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis. Am J Clin Oncol (2013) 0.91
Hand-assisted laparoscopic ureterolysis to treat ureteral obstruction secondary to idiopathic retroperitoneal fibrosis: assessment of a novel technique and initial series. Urology (2006) 0.91
Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis. Carcinogenesis (2008) 0.90
Thermal ablation of renal cell carcinoma: triage, treatment, and follow-up. J Vasc Interv Radiol (2010) 0.89
Hematuria: etiology and evaluation for the primary care physician. Can J Urol (2008) 0.89
Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Urology (2004) 0.89
The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol (2002) 0.89
Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. Am J Clin Oncol (2015) 0.89
The dilemma of a rising prostate-specific antigen level after local therapy: what are our options? Semin Oncol (2013) 0.88
Transition from pure laparoscopic to robotic-assisted radical prostatectomy: a single surgeon institutional evolution. Urol Oncol (2010) 0.88
The prostate cancer unit: a multidisciplinary approach for which the time has arrived. Eur Urol (2011) 0.87
Pathologic comparison of laparoscopic versus open radical retropubic prostatectomy specimens. Urology (2003) 0.87
Correlation of pathology with tumor size of renal masses. Can J Urol (2007) 0.87
Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. Semin Oncol (2013) 0.87
The addition of robotic surgery to an established laparoscopic radical prostatectomy program: effect on positive surgical margins. Can J Urol (2008) 0.86
Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes. Am J Clin Oncol (2015) 0.85
Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol (2013) 0.84
STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol (2013) 0.84
The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nat Rev Urol (2012) 0.84
Postprostatectomy radiation therapy: an evidence-based review. Future Oncol (2011) 0.83
Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells. PLoS One (2012) 0.83
Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. Can J Urol (2012) 0.83
High-frequency Doppler US of the prostate: effect of patient position. Radiology (2002) 0.82
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol (2014) 0.82
Hand-assisted laparoscopic nephroureterectomy: analysis of distal ureterectomy technique, margin status, and surgical outcomes. Urology (2005) 0.82
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol (2009) 0.81
Perioperative morbidity of laparoscopic radical prostatectomy compared with open radical retropubic prostatectomy. Urol Oncol (2004) 0.81
Surgical management of metastatic disease to the adrenal gland. Semin Oncol (2008) 0.81
Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. PLoS One (2011) 0.81
Identifying barriers to patient acceptance of active surveillance: content analysis of online patient communications. PLoS One (2013) 0.81
Transperitoneal robotic-assisted laparoscopic prostatectomy after prosthetic mesh herniorrhaphy. JSLS (2009) 0.80
Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res (2004) 0.80